Helping you make informed decisions in a continually changing environment.

overview

A History of Advancing Drug Discovery Research

A History of Advancing Drug Discovery Research

Founded in 1983, the Gentest brand initially focused on the use of cultured human cells in GLP genotoxicity assays. In 1985, the company expanded research activities into the area of xenobiotic metabolism by developing cytochrome P450 cDNA-expression approaches. This led to the first commercial offering of cDNA-expressed human cytochrome P450 enzymes in 1990. Since that time, the range of Gentest offerings has increased dramatically, from recombinant systems to in vivo-like systems like primary hepatocytes. Now, as part of Corning Life Sciences, the Gentest offerings continue to grow, helping you stay on the leading edge of drug discovery and development.

Our scientists are internationally recognized as leaders and innovators in cytochrome P450 cDNA-expression, in vitro xenobiotic metabolism, and drug transporter techniques. Our demonstrated commitment to research has been rewarded by the receipt of several competitive NIH grants. The results and applications of our research are reported in peer reviewed journals and at international symposia by our scientists, colleagues, and customers interested in xenobiotic metabolism.

Corning Recombinant Enzyme Products

Corning Recombinant Enzyme Products

Supersomes™ Enzymes are ideal for screening high throughput drug interactions, studying slowly metabolized chemicals, or manufacturing large-scale production of metabolites for structural identification. Corning SupersomesEnzymes areprepared from baculovirus-transfected insect cells with very high levels of catalytic activities (typically 6-fold higher than an average HLM sample).

Evaluation of Calibration Curve-based Approaches

Evaluation of Calibration Curve-based Approaches

In a study conducted by Zhang et al, researchers were able to use Corning Gentest Human CryoHepatocytes to assess the amount of P450 induction in the liver by analyzing the concentration response curves of CYP3A4 mRNA in vitro, and established a predictive relationship between the chance in AUC in humans and parameters from CYP3A4 mRNA activity in vivo.

This research supports the use of calibration curve models and human hepatocytes to predict CYP3A4 induction potential in human patients, which can pave the way for clinical trials of potential new drug...

TransportoCells FAQs

With the introduction of the solute carrier (SLC) over-expressing Corning TransportoCells, we have expanded our TransportoCells offering to conduct screening and use a step-wise approach for drug-drug interaction assays.

Questions? Download this FAQ on our new line of cryopreserved SLC transporter cells, or contact us.

See how our recently introduced TransportoCells products support in vitro assessment of drug interaction with SLC transporters. This new model provides a convenient “thaw and go” cell-based model with robust activity and consistent performance.